Cardiovascular Implants Global Market Report 2024

The cardiovascular implants market size has grown strongly in recent years. It will grow from $24.81 billion in 2023 to $26.8 billion in 2024 at a compound annual growth rate (CAGR) of 8%. The growth observed in the historical period can be attributed to factors such as the aging population and associated cardiovascular risks, lifestyle-related cardiovascular risk factors, advancements in diagnostic technologies, increasing awareness, and screening programs, as well as government initiatives focused on cardiovascular health.

The cardiovascular implants market size is expected to see strong growth in the next few years. It will grow to $34.59 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to the adoption of personalized medicine approaches, a focus on minimally invasive procedures, global collaboration in cardiovascular research, healthcare policy emphasis on preventive interventions, and the shift towards patient-centric cardiovascular care. Major trends expected in the forecast period include advancements in drug-eluting stents, the rise of next-generation heart valves, increasing integration of artificial intelligence (AI), a focus on minimally invasive implantation techniques, the development of personalized and patient-specific implants, and the emergence of leadless pacemakers.

The anticipated increase in the prevalence of heart disorders is poised to drive the expansion of the cardiovascular implants market in the future. Heart disorders encompass a range of medical conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, and valve disorders. The demand for cardiovascular implants, such as stents and pacemakers, is propelled by the prevalence of heart diseases such as coronary artery disease and heart failure, as these implants play a crucial role in treating these conditions. They provide support to the heart and circulation in patients with heart failure, aid in maintaining a regular heart rhythm, and monitor heart activity. For example, in April 2023, the British Heart Foundation reported that the number of deaths in Scotland from heart and circulatory illnesses increased from 17,448 in 2020 to 17,639 in 2021. Moreover, the number of deaths from coronary heart disease in the UK rose from 64,170 in 2020 to 65,579 in 2021. Hence, the growing prevalence of heart disorders is fueling the growth of the cardiovascular implants market.

The increase in the aging population is expected to drive the growth of the cardiovascular implants market in the future. The aging population reflects a demographic shift characterized by a higher proportion of individuals aged 60 and above in a population. Cardiovascular implants play a crucial role in managing and treating cardiovascular diseases prevalent in older individuals, contributing to improved quality of life, increased longevity, and overall better health outcomes. According to the World Health Organization in October 2022, globally, 1 in 6 individuals is projected to be 60 or older by 2030, and this number is expected to reach 2.1 billion elderly people by 2050. Therefore, the rise in the aging population is a key factor driving the growth of the cardiovascular implants market.

The impediment to the growth of the cardiovascular implant market is the high cost associated with left ventricular devices. The incremental cost-effectiveness ratio for destination-therapy left ventricular assist devices (LVAD) over optimal medical management is relatively high. While LVADs improve the quality of life in non-inotrope-dependent heart failure patients, they substantially increase lifetime costs. For example, a study in August 2020 revealed that LVAD patients had higher lifetime costs, with the total cost for the LVAD arm being $551,934 compared to $334,117 for the control group. Consequently, the high cost of left ventricular assist devices poses a restraint on the growth of the cardiovascular implant market.

Leading companies in the cardiovascular implants market are intensifying their focus on incorporating advanced technology, including artificial intelligence (AI), to optimize market profits and enhance precision in patient care and treatment. Advancements in cardiac monitoring technology involve continuous tracking and recording of a patient's heart activity for the diagnosis and management of heart conditions. In June 2023, BIOTRONIK SE & Co. KG launched the BIOMONITOR IV implantable cardiac monitor (ICM), the first globally, combining SmartECG technology with artificial intelligence. This innovation reduces false-positive detections by 86% while retaining 98% accuracy in detecting real episodes. BIOMONITOR IV offers additional benefits, including extended battery life and wireless connectivity for smooth data transmission and remote monitoring, reducing the need for frequent in-person clinic visits.

In April 2023, Abbott Laboratories acquired Cardiovascular Systems Inc. for $890 million, aiming to enhance its solutions for treating vascular disease. This strategic acquisition makes Cardiovascular Systems Inc. a wholly owned subsidiary of Abbott and strengthens Abbott's position in providing innovative solutions for peripheral and coronary vascular disease.

Major companies operating in the cardiovascular implants market report are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B. Braun Melsungen AG, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Cook Medical Incorporated, Teleflex Incorporated, Kyoto Medical Planning Co. Ltd., Abiomed Inc., Livanova PLC, BIOTRONIK SE & Co. KG, CryoLife Inc., Endologix Inc., Sorin Group, Berlin Heart GmbH, REVA Medical LLC., Syncardia Systems LLC, Elixir Medical Corporation, Fortimedix Surgical B.V., AMG International GmbH, CHF Solutions Inc., Proxy Biomedical Ltd., Calon Cardio-Technology Ltd., InspireMD Inc., Neovasc Inc., Shree Pacetronix Ltd., Vascutek Ltd (Terumo Corporation)

North America was the largest region in the cardiovascular implants market in 2023. The regions covered in the cardiovascular implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiovascular implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cardiovascular implants are medical devices surgically placed within the cardiovascular system to manage heart and vascular conditions. These devices are strategically inserted into the cardiovascular system to address conditions such as blocked arteries, irregular heart rhythms, or valve defects. The primary goal is to restore normal heart function and improve blood circulation.

The main types of products categorized under cardiovascular implants include coronary stents, implantable cardioverter defibrillators (ICD), heart valves, implanted cardiac pacemakers, cardiac resynchronization therapy (CRT) devices, and peripheral stents. A coronary stent is a small mesh tube inserted into a narrowed or blocked coronary artery to maintain its openness. Various materials, including metals and alloys, polymers, and biological materials, are used in the manufacturing of these implants. They find applications in treating conditions such as arrhythmias, acute myocardial infarction, myocardial ischemia, and others. These cardiovascular implants are utilized by various end-users, including hospitals, ambulatory surgical centers, and cardiac centers.

The cardiovascular implants market research report is one of a series of new reports that provides cardiovascular implants market statistics, including cardiovascular implants industry global market size, regional shares, competitors with a cardiovascular implants market share, detailed cardiovascular implants market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular implants industry. This cardiovascular implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiovascular implants market consists of sales of aneurysm stent-grafts, cardiac resynchronization therapy (CRT) devices, ventricular assist devices, and peripheral vascular stents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.